Purine derivatives having phosphodiesterase iv inhibition activity
Patent 6413975 Issued on July 2, 2002. Estimated Expiration Date: March 31, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/263.2, Additional hetero ring attached directly or indirectly to the purine ring system by nonionic bonding514/263.4, Nitrogen bonded directly to ring carbon of the purine ring system (e.g., adenine, etc.)544/267, At 2- and 6-positions (e.g., theophyllines, etc.)544/268, Additional polycyclo ring system, which is not another purine, having a hetero ring as one of the cyclos544/271, Having -C(=X)-, wherein X is chalcogen attached directly or indirectly to the purine ring system by nonionic bonding or halogen bonded directly at 8-position (e.g., theophylline acetate, 8-chlorotheophylline, etc.)544/272, Nitrogen attached directly or indirectly to the purine ring system by nonionc bonding544/273, Positions other than 2- and 6- are unsubstituted or hydrocarbyl or hydro- carboyl substituted only (e.g., theophylline, etc.)544/276, Nitrogen attached directly or indirectly to the purine ring system by nonionic bonding544/277Nitrogen attached directly or indirectly to the purine ring system by nonionic bonding
Disclosed are compounds of the formula: ##STR1##whereinR3, R6a, R6b and R8 are substituted as disclosed herein. The compounds are effective in effecting PDE IV inhibition in patients in need thereof.
Other References
Fuji et al, Chem Pharm Bull 41(8) 1363, Aug. 1993.
Yu et al, Phytochemistry 20(6) 1191, Jun. 1981.
Robins, JACS, 74, 1952, 3624-
Stafford and Feldman, "Annual Reports in Medicinal Chemistry", Academic Press, San Diego, 1966, Chapt. 8, p. 76-78
Henry Koppel & Roland Robins, JOC, 23, 1958, 1457-1460
Giner-Sorolla, Alfred, Segarra, Jay T., Hadden, John W., Nucleic Acid Chem., vol. 4, 10-15
Girshovich, Chem Abs 116, 173873 (1991)
Montgomery, J.A.C.S. 81, 3963 (1959)
Elion, Chem Abe 53, 6243h (1957)
Isomura, Y. et al., "Studies on the synthesis and Anti-Inflammatory Activity of 2,6-Di-tert-butylphenols with a Heterocyclic Group at the 4-Position. I." Chem. Pharm. Bull. 31 (9) 3168-3178 (1983)
Ashton, et al., "Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Synthesis and Biological Activities of 3-(Cyclopentyloxy)-4-methoxybenzamides and Analogues." J. Med. Chem., vol. 37, No. 11 1696-1703 (1994)
K.R.H. Woolridge and R. Slack, "The Synthesis of Some 6-Thioxanthines." Annex IV, 1863-1868 (1962)
Fuji, J. Med. Chem. 22, 125 (1979)
Reitz, J. Org. Chem 55, 5761 (1990)
Itaya, Zet. Letters 23, 2203 (1982)
Enoki, Chem Abs 85, 5692 (1976)
Kazimierczuk, Chem Abs 82, 125358 (1974)
Ulbricht, Chem Abs 75, 49027b (1971)
Aida, Chem Abs 86, 43746 (1976)
Enoki, Chem Abs 84, 180299 (1976)
G.T. Rogers et al.: "Synthesis of 3-methylisoguanine '6-Amino-3-methylpurin-2(3H)-One!" Journal of the Chemical Society C, No. 12, 1971, pp. 2364-2366, XP002095992
Elion, G. "Some new n-methylpurines" CIBA Foundation Symp. Chem. Biol. Purines, 1957, pp.39-49
Glusenkamp, K, et al., Tautomer-specific anti-(M-3-substituted)-adenine antibodies: new tools in molecular dosimetry & epidemiology, Agnew Chem. Int. Ed. Engl. 1993, 32, No. 11, pp. 1640-164
March 31, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
